Background
==========

Common mental disorders, i.e. depressive disorder, anxiety disorder and somatoform disorder, are the most prevalent of all mental disorders, with the highest burden in terms of work absenteeism and utilization of health care services \[[@B1]-[@B3]\]. In the case of depressive disorder, 80% of the costs are due to production loss \[[@B4]\]. People with major depressive disorder are absent from work 8 to 9 times as often as people without this disorder\[[@B5],[@B6]\]. Mental problems account for 30% of disability leave, and in the majority of cases the employees have never been diagnosed or treated by a psychiatrist\[[@B7]\]. Complaints of the musculoskeletal system account for another 40%, and are considered to be possibly unrecognized somatoform, depressive and anxiety disorder\[[@B8]\]. Anxiety disorders such as generalized anxiety disorder and panic disorder, are also highly prevalent, and have a high societal impact\[[@B9]\]. Moreover, on average, absence from work due to mental disorders has a longer duration than absence caused by physical illness\[[@B10],[@B11]\].

Guidelines for evidence-based treatments are available for depressive disorder, anxiety disorder and somatoform disorder\[[@B12]-[@B15],[@B30]\]. However, for patients with these disorders in the primary care setting there is an inadequate offer of diagnostic and therapeutic help\[[@B16]\]. They often do not receive treatment, and present in the primary care setting with medically unexplained symptoms, thus burdening the General Practitioner (GP) and the health care setting in general with numerous visits and referrals to medical specialists\[[@B17]-[@B20]\]. The GP is misdirected by the combination of the patient\'s presentation with these symptoms and the fact that he has to meet competing demands in his practice\[[@B21]\]. If a mental disorder is recognized, the feasibility of these guidelines appears to be low, because many GPs feel incapable of delivering the cognitive behavioural interventions described in the guidelines, and also because of frequent care avoidance by the patients\[[@B22],[@B23]\]. Therefore, care as usual (CAU) often implies fragmented patient-led care that is not cost-efficient, including referral to medical specialists to exclude somatic disease. This is a pity, because most of these patients can be treated effectively\[[@B24]-[@B27]\] in the primary care setting, if recognition and treatment is enhanced.

In the occupational health setting, that can be considered to have similar characteristics in terms of prevalence, diagnosis and treatment of mental disorders, as the primary care setting, a similar situation exists, but less attention has been paid to the diagnosis and treatment of common mental disorders. Guidelines for mental disorders in occupational health have been developed by the Dutch Association for Occupational Health (NVAB): guidelines for mental complaints\[[@B28]\], and, supplementary to the multidisciplinary guidelines for the diagnosis and treatment of depression\[[@B29]\], a module for depression and work. Guidelines have also been developed for the treatment of somatoform disorder in the occupational setting\[[@B30]\]. The NVAB guidelines for mental complaints\[[@B28]\] focus on stress and adjustment disorders in relation to the process of returning to work, functioning and the treatment of work-related problems. However, adequate recognition, treatment and criteria for the referral of patients for specialist treatment of mental disorders are not an important part of the guideline.

The implementation of the NVAB guidelines so far has led to a reduction in minor mental problems and in short-term work absenteeism. However, the amount of mental problems leading to disability leave remains high, indicating that occupational physicians (OPs) are still not accustomed to the diagnosis and treatment of mental disorders. In the Dutch legislation, responsibility for medical treatment is separated from responsibility for guidance in sickness absence and return to work (RTW). Only recently the OPs in the Netherlands have been enabled by law to refer employees to curative medical specialists if such treatment for a present mental disorder is needed for good functioning or RTW. Very little research has yet focussed on interventions for patients with common mental disorders, specifically aimed at RTW\[[@B3],[@B31]\]. For many years it was assumed that recovery from symptoms would automatically lead to a recovery of functioning at work. However, it appears that focussing on functioning in the work setting contributes to a faster and a more lasting RTW in patients with mental disorders\[[@B32]\]. Thus, treatment of common mental disorder should not only focus on symptoms, but also on work-related functioning. This implies a broadening of the focus from the individual patient to the patient and the work context. Recovery should therefore also include the work setting: patients resume their work as soon as possible and are supported in this by their therapist \[[@B24]\]. For example, in a study carried out by Van der Klink et al. \[[@B25]\] among patients with adjustment disorders, in which the intervention was provided by OPs, the intervention had a shorter duration of sick leave than the control group. Therefore, in the present study we try to deal with sickness absence by embedding the treatment in the occupational setting and by including an intervention provided by the OP, after a consultation with a psychiatrist. Stimulating patients in RTW requires an active approach that encompasses specific interventions tailored to the needs created by the specific common mental disorder that the patient suffers from.

To summarize, in the present study design the following elements are central: training of OPs in the diagnosis and treatment of employees with depressive disorder, anxiety disorder or somatoform disorder; supportive psychiatric consultation aimed at the formulation of a diagnosis and a treatment plan, including suggestions for RTW adapted to the specific needs of the patients due to their specific disorder; and training of the consultant psychiatrists to provide not only a diagnosis and a treatment plan, but also to provide suggestions for successful strategies aimed at the improvement of work functioning.

Methods/Design
==============

Objectives
----------

The primary aim of the present study is to test the effectiveness of psychiatric consultation embedded in a training program for OPs, aimed at the diagnosis and treatment of common mental disorders in employees who are on sick leave, with a focus on work functioning. The secondary aim is to estimate the cost-effectiveness of the intervention.

Hypothesis
----------

In a randomized controlled study comparing psychiatric consultation with CAU provided by the OP, patients in the intervention group will improve in terms of general functioning, RTW, severity of the mental disorder and quality of life.

Study design
------------

The study is a two-armed cluster-randomized pragmatic clinical trial with randomization among the OPs. This intervention cannot be blinded, so the OPs might also use the techniques that they learned in the intervention to treat control patients. Randomization among OPs eliminates the danger of such contamination, and thus dilution of the effect. The outcome parameters will be measured by a blinded research assistant. This procedure has already been reported in detail elsewhere\[[@B33]\].

Recruitment of OPs and consultant psychiatrists
-----------------------------------------------

The study has been designed and will be carried out in co-operation with ArboNed, and Arbounie, two companies providing company medical care. Together they cover almost half of the working population in the Netherlands. Within these two companies, 40 OPs from four offices in two regions will be recruited. Four consultant psychiatrists will also be recruited.

Recruitment of patients
-----------------------

The aim is to include employees who have been absent from work for a minimum of 6 weeks and a maximum of 52 weeks, do not plan to resume work within the coming 6 weeks, and have been screened on either the Patient Health Questionnaire (PHQ) or the Whitely Index.

All patients who visited an OP within the past 6 months will be selected from the medical files, and will receive a letter describing the purpose of the study, together with an informed consent form for the screening procedure and the baseline questionnaires. Patients visiting an OP during the inclusion period will also be invited to participate in the study. They will also receive the informed consent form, together with the baseline questionnaires.

Patients will be included if they reach a cut off score of \>15 on the PHQ9\[[@B34]\] or \> 3.5 on the Whitely Index\[[@B35]\] and have given informed consent for participation in the study. The Mini-International Neuropsychiatric Interview (MINI.)\[[@B36],[@B37]\] will be administered for the classification of symptoms according to DSM-IV\[[@B38]\]. In the intervention group, the patients selected in this way will have a consultation with a psychiatrist in addition to the treatment provided by the OP; in the control group the patients receive CAU provided by their OP.

Exclusion criteria
------------------

Patients will be excluded from the study if they are suicidal, psychotic or suffering from dementia, have insufficient knowledge of the Dutch language to fill in the questionnaires, or are addicted to drugs or alcohol. Patients who are already receiving psychiatric treatment can be included if mutual agreement is achieved with their current care-giver. Patients will also be excluded if they are involved in legislative procedures for unemployment compensation. (See Figure [1](#F1){ref-type="fig"} for a flowchart of the participants.)
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Intervention
------------

### Training

All OPs will receive training in the diagnosis and treatment of common mental disorder in three sessions. They will be trained in the use of tools for screening and diagnostics, and cognitive-behavioural and reattribution techniques. The psychiatrists will be trained to make a diagnosis, and a treatment plan, and to formulate suggestions aimed at RTW specifically tailored to the patient\'s mental disorder. The psychiatrists will see the patient once and make a written report to the OP by consultation letter. A psychiatrist and an OP from the research group will provide the training.

### Treatment in the intervention group

The care provided in the intervention group will follow a collaborative care approach: patient-tailored care executed within a team of the OP, the patient, the consulting psychiatrist, and in some cases the General Practitioner (GP). According to a previously developed method\[[@B20]\], a treatment plan will be formulated by the consultant psychiatrist, together with the patient. This will be specifically tailored to the diagnosed common mental disorder, with a focus on RTW. The OP will be informed about the treatment recommended by the consultant psychiatrist. Subsequently, the OP will co-ordinate the care and evaluate the treatment steps. During the consultation, the psychiatrist will make an inventory of treatment that has been offered to the patient before, and will decide, together with the patient, whether more intensive treatment is needed. This depends on the severity of symptoms, the perceived well-being of the patient, and on the level of general functioning according to the GAF score on Axis V of the DSM-IV\[[@B38]\] a method that has been described elsewhere\[[@B39]\].

### Treatment in the control group

Half of the OPs will be randomized to the control group, and their patients will receive CAU. The actual content of the CAU (e.g. medication, number of contacts with OP, GPs and specialists) will be assessed according to the Scale for Medical Utilisation of Health Services\[[@B40]\].

Outcome parameters
------------------

### 1. Primary outcome measure

The primary outcome measure will be the level of functioning, as assessed with the SF-20\[[@B41]-[@B43]\].

### 2. Secondary outcome measures

The severity of the symptoms will be measured with the PHQ\[[@B35]\] and the SCL-90\[[@B44]\]. Quality of life will be assessed with the EQ-5D\[[@B45],[@B46]\] and the SF-20, both of which are validated tools for the assessment of general health-related quality of life.

In addition to the evaluation of improvement in general functioning, an attempt will also be made to assess the cost-utility of psychiatric consultation compared to CAU. Therefore, an estimate will be made of the direct medical costs and productivity costs. The necessary data collected by means of the Trimbos/*i*MTA questionnaire for Costs associated with Psychiatric Illness (TiC-P)\[[@B47],[@B48]\].

Additional outcome measures will be the MVI-20, a questionnaire assessing fatigue\[[@B49]\] and the ALCOS-12 that assesses general competence, resilience and initiative in an employee\[[@B50]\].

Process measures will be satisfaction of the employee with the OP (VAS) and compliance with the advice given by the consultant psychiatrist.

Baseline measurements will take place before inclusion (T~0~), and follow up measurements will take place at 3 months with the TiC-P and EQ-5D (T~1~) and at 6 months (T~2~).

Sample size
-----------

In the present study, there will be cluster randomization among the OPs, and Multi Level Analysis (MLA) will be performed with OPs at the first hierarchical level and patients at the second level. The SF-20 will be the primary outcome measure for the power calculation, which will be based on the design effect. This is the factor needed to enlarge the total sample size that would be reached the same standard error that would be reached using randomization between patients and a General Linear Model (GLM) analysis in the sample. The formula is\[[@B51]\]: **Design effect = 1+(n-1)ρ~1~**

n = the mean sample size at the second hierarchical level (patient level in this instance) and ρ~1~= the intra-class correlation

If a GLM with repeated measures would be used in a study with randomization among patients, with a variance of 1.0, then a sample size of 2 × 10 would be needed for a power of 0.90. A variance of 1.0 as intraclass correlation would be acceptable as a presumption if the contrast between the two groups would be rather high, i.e. if the CAU that was provided was different to the consultation intervention provided in the different practices. We presume that this is the case, because psychiatric consultation in addition to OP care, as in the present study, is a new method for the Netherlands that differs substantially from normal standards of care \[[@B20]\]. Under these assumptions, in a MLA study such as this one, with an SD of 1.0, and a mean number of 3 patients per OP, this would result in a design effect of 3, implying that N should be multiplied by 3, compared to the number needed for a power of 0.90 in patient-randomised GLM analysis. If in such a study a standardized difference of 1.0 was detected, a sample size of 2 × 30 completers would be needed in order to detect a clinically relevant significant improvement of 25%, compared to the spontaneous recovery in the control group on the SF-20. This is the sample size that we aim to achieve in this study\[[@B52],[@B53]\].

Analysis
--------

Intention-to-treat analysis will be performed by means of MLA, with OPs in the primary hierarchical level. Subsequently, at the secondary hierarchical level, patient characteristics influencing the outcome will be analysed. If differences in outcome are found in MLA, the effect size will be estimated by Chi-square analysis and described in Cohen\'s d\[[@B54]\]. To control for possible skew ness in the randomized groups, as far as the distribution of confounders is concerned, propensity scores will be calculated\[[@B55]\]. Possible confounders, such as age, gender, history of mental disorder, history of treatment, fatigue, resilience, and satisfaction and compliance of the employee, will be entered as variables in the analysis.

Time-frame of the study
-----------------------

The preparatory period will be 6 months. Subsequent to the approval of the Medical Ethics Committee, the OPs will be recruited and the psychiatrists will be trained. The inclusion and intervention phase will take 12 months. The follow-up phase will be 12 months, and data-analyses will last for 6 months. The total duration of the study will be 3 years.

Ethical principles
------------------

The study has been planned, and will be executed in accordance with the principles laid down in the Helsinki declaration (Edinburgh, Scotland amendment, October 2000). Participation in the study will be voluntary, and written informed consent will be obtained. Patients will be explicitly informed of the fact that they can withdraw their consent to participate at any time, without specification of reasons and with no negative consequences for their future medical treatment. Patients who wish to withdraw from the study will receive CAU. The study has been approved by the Medical Ethics Committee of the METiGG, Kamer Zuid protocol 5.127.

Discussion
==========

Strengths and limitations
-------------------------

One limitation of the study might be that the organization of care in companies could be a hazard, because this sector is under pressure to work more and more efficiently. It might also be difficult to establish regular contact between OPs, consultant psychiatrists and GPs, because OPs generally work supraregionally. Specific attention will be paid to limitations in implementation due to regional differences.

A strength of the study might be that early consultation could be very helpful to enhance early RTW, and thus might also improve recovery from a mental disorder. By embedding the psychiatric consultation in the company care setting, timely access to specialist care will be improved and discontinuity of care will be avoided.
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